DiaGenic
DiaGenic Cutting Jobs as Part of Cost Reduction Program
NEW YORK (GenomeWeb News) – Norwegian biomarker diagnostics firm DiaGenic today announced the initiation of a cost reduction program, which includes the elimination of an undisclosed number of jobs.
Norwegian molecular diagnostic developer DiaGenic said this week that it has adopted Life Technologies' recently launched QuantStudio Dx platform to further enable development of its pipeline of multi-biomarker blood-based molecular assays for Alzheimer's disease.
DiaGenic has named Paul de Potocki as president and CEO, effective in September.
DiaGenic Gets $1.3M Grant for Alzheimer's Dx Project
NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.
DiaGenic said this week that CEO Erik Christensen has resigned.
Christensen will "continue to provide consultative support to the company on partner interactions, licensing and other business activities," DiaGenic said in a statement.
Jun 3, 2011
Diagenic Exercises 10-for-1 Reverse Stock Split
Oct 7, 2010
DiaGenic Raises $12.1M in Private Placement
Jun 3, 2010
Jan 21, 2010
Jan 20, 2010